Pharmacokinetic evaluation of teriflunomide for the treatment of multiple sclerosis

Expert Opinion on Drug Metabolism and Toxicology

Volumn 9, Issue 8, 2013, Pages 1025-1035

  Wiese, Michael D ^a   Rowland, Andrew ^b   Polasek, Thomas M ^b   Sorich, Michael J ^a   O'Doherty, Catherine ^a  

^a UNIVERSITY OF SOUTH AUSTRALIA   (Australia)

^b FLINDERS UNIVERSITY   (Australia)

Author keywords

ABCG2; Dihydroorotate dehydrogenase; Leflunomide; Multiple sclerosis; Pharmacokinetics; Teriflunomide; TFMA oxalinate

Indexed keywords

ACTIVATED CARBON; ALEMTUZUMAB; AMINOTRANSFERASE; BETA INTERFERON; COLESTYRAMINE; CYTOCHROME P450 1A2; CYTOCHROME P450 2C19; CYTOCHROME P450 3A4; DACLIZUMAB; DIHYDROOROTATE DEHYDROGENASE; DRUG METABOLITE; FINGOLIMOD; FUMARIC ACID DIMETHYL ESTER; GLATIRAMER; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; JANUS KINASE 1; JANUS KINASE 3; LAQUINIMOD; LEFLUNOMIDE; MATRIX METALLOPROTEINASE; METHOTREXATE; MITOXANTRONE; NATALIZUMAB; OCRELIZUMAB; PLACEBO; RITUXIMAB; TERIFLUNOMIDE; TRIFLUOROMETHYLANILINE OXALINIC ACID; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ALOPECIA; ARTICLE; AUTOIMMUNE DISEASE; BRADYCARDIA; CARDIOTOXICITY; DEPRESSION; DIARRHEA; DNA SYNTHESIS INHIBITION; DOSE RESPONSE; DRUG ABSORPTION; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG FATALITY; DRUG HALF LIFE; DRUG MARKETING; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EXPANDED DISABILITY STATUS SCALE; FLU LIKE SYNDROME; G1 PHASE CELL CYCLE CHECKPOINT; GASTROINTESTINAL SYMPTOM; GENE MUTATION; GOODPASTURE SYNDROME; HAIR DISEASE; HEART MUSCLE CONDUCTION DISTURBANCE; HUMAN; HYPERTENSION; IMMUNOMODULATION; INFECTION; INFUSION RELATED REACTION; INJECTION SITE REACTION; JUVENILE RHEUMATOID ARTHRITIS; KIDNEY ALLOGRAFT REJECTION; LEUKEMIA; LIVER FUNCTION; LIVER TOXICITY; LYMPHOCYTE PROLIFERATION; LYMPHOCYTOPENIA; MEDICAL LITERATURE; MULTIPLE SCLEROSIS; NAUSEA; NEUROPATHY; NEUTROPENIA; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OPPORTUNISTIC INFECTION; PATHOPHYSIOLOGY; PATIENT COMPLIANCE; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PNEUMONIA; PREGNANCY DISORDER; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; PSORIATIC ARTHRITIS; RACE DIFFERENCE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; RELAPSE; RETINA MACULA EDEMA; RHEUMATOID ARTHRITIS; SEX DIFFERENCE; SIDE EFFECT; SINGLE DRUG DOSE; SINGLE NUCLEOTIDE POLYMORPHISM; SKIN ALLERGY; T LYMPHOCYTE; THYROID DISEASE; TREATMENT OUTCOME; TREATMENT RESPONSE; TUBERCULOSIS; UNSPECIFIED SIDE EFFECT; VIRUS INFECTION;

ADMINISTRATION, ORAL; ANIMALS; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; CROTONATES; DISEASE MODELS, ANIMAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; ISOXAZOLES; MULTIPLE SCLEROSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TOLUIDINES;

EID: 84880374675     PISSN: 17425255     EISSN: 17447607     Source Type: Journal    
DOI: 10.1517/17425255.2013.800483     Document Type: Article

References (76)

1. Hayter SM, Cook MC. Updated assessment of the prevalence, spectrum and case definition of autoimmune disease. Autoimmun Rev 2012;11(10):754-65
2. Orton SM, Herrera BM, Yee IM, et al. Sex ratio of multiple sclerosis in Canada: A longitudinal study. Lancet Neurol 2006;5(11):932-6
3. Ascherio A, Munger KL, Luenemann JD. The initiation and prevention of multiple sclerosis. Nat Rev Neurol 2012;8(11):602-12
4. Weinshenker BG, Bass B, Rice GP, et al. The natural history of multiple sclerosis: A geographically based study. I. Clinical course and disability. Brain 1989;112(Pt 1):133-46
5. Tremlett H, Zhao Y, Rieckmann P, Hutchinson M. New perspectives in the natural history of multiple sclerosis. Neurology 2010;74(24):2004-15
6. Noseworthy JH, Lucchinetti C, Rodriguez M, Weinshenker BG. Multiple sclerosis. N Engl J Med 2000;343(13):938-52
7. Eikelenboom MJ, Killestein J, Izeboud T, et al. Expression of adhesion molecules on peripheral lymphocytes predicts future lesion development in MS. J Neuroimmunol 2005;158(1-2):222-30
8. Comabella M, Khoury SJ. Immunopathogenesis of multiple sclerosis. Immune Mech New Ther Strateg Mult Scler 2012;142(1):2-8
9. Ropper AH. The "poison chair" treatment for multiple sclerosis. N Engl J Med 2012;367(12):1149-50
10. Rudick RA, Stuart WH, Calabresi PA, et al. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med 2006;354(9):911-23
11. Ford C, Goodman AD, Johnson K, et al. Continuous long-term immunomodulatory therapy in relapsing multiple sclerosis: Results from the 15-year analysis of the US prospective open-label study of glatiramer acetate. Mult Scler 2010;16(3):342-50
12. Trojano M, Pellegrini F, Fuiani A, et al. New natural history of interferon-beta-treated relapsing multiple sclerosis. Ann Neurol 2007;61(4):300-6
13. Trojano M, Pellegrini F, Paolicelli D, et al. Real-life impact of early interferon beta therapy in relapsing multiple sclerosis. Ann Neurol 2009;66(4):513-20
14. Renoux C, Suissa S. Immortal time bias in the study of effectiveness of interferon-beta in multiple sclerosis. Ann Neurol 2008;64(1):109-10; author reply 10
15. Shirani A, Zhao Y, Karim ME, et al. Association between use of interferon beta and progression of disability in patients with relapsing-remitting multiple sclerosis. JAMA 2012;308(3):247-56
16. Clinical Trials website. Available from: Http://www.clinicaltrials.gov
17. FDA website. Available from: Http://www.fda.gov
18. Buzzard KA, Broadley SA, Butzkueven H. What do effective treatments for multiple sclerosis tell us about the molecular mechanisms involved in pathogenesis? Int J Mol Sci 2012;13(10):12665-709
19. Gonsette RE. Mitoxantrone in progressive multiple sclerosis: When and how to treat? The Progressive Phase of Multiple Sclerosis: Pathology and Treatment 7th European Charcot foundation Symposium. J Neurol Sci 2003;206(2):203-8
20. Polman CH, O'Connor PW, Havrdova E, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006;354(9):899-910
21. Major EO. Progressive multifocal leukoencephalopathy in patients on immunomodulatory therapies. Annu Rev Med 2010;61:35-47
22. Bloomgren G, Richman S, Hotermans C, et al. Risk of natalizumab- associated progressive multifocal leukoencephalopathy. N Engl J Med 2012;366(20):1870-80
23. Kappos L, Bates D, Edan G, et al. Natalizumab treatment for multiple sclerosis: Updated recommendations for patient selection and monitoring. Lancet Neurol 2011;10(8):745-58
24. Matloubian M, Lo CG, Cinamon G, et al. Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1. Nature 2004;427(6972):355-60
25. Noda H, Takeuchi H, Mizuno T, Suzumura A. Fingolimod phosphate promotes the neuroprotective effects of microglia. J Neuroimmunol 2013;256(1-2):13-18
26. Di Menna L, Molinaro G, Di Nuzzo L, et al. Fingolimod protects cultured cortical neurons against excitotoxic death. Pharmacol Res 2013;67(1):1-9
27. Cohen JA, Barkhof F, Comi G, et al. Oral Fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 2010;362(5):402-15
28. Kappos L, Radue E-W, O'Connor P, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 2010;362(5):387-401
29. Gilleece MH, Dexter TM. Effect of Campath-1H antibody on human hematopoietic progenitors in vitro. Blood 1993;82(3):807-12
30. Thompson SAJ, Jones JL, Cox AL, et al. B-cell reconstitution and BAFF after alemtuzumab (Campath-1H) treatment of multiple sclerosis. J Clin Immunol 2010;30(1):99-105
31. Coles AJ, Fox E, Vladic A, et al. Alemtuzumab versus interferon beta-1a in early relapsing-remitting multiple sclerosis: Post-hoc and subset analyses of clinical efficacy outcomes. Lancet Neurol 2011;10(4):338-48
32. Cohen JA, Coles AJ, Arnold DL, et al. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: A randomised controlled phase 3 trial. Lancet 2012;380(9856):1819-28
33. Comi G, Jeffery D, Kappos L, et al. Placebo-controlled trial of oral laquinimod for multiple sclerosis. N Engl J Med 2012;366(11):1000-9
34. Wynn D, Kaufman M, Montalban X, et al. Daclizumab in active relapsing multiple sclerosis (CHOICE study): A phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta. Lancet Neurol 2010;9(4):381-90
35. Bielekova B, Catalfamo M, Reichert-Scrivner S, et al. Regulatory CD56bright natural killer cells mediate immunomodulatory effects of IL-2Ra-targeted therapy (daclizumab) in multiple sclerosis. Proc Natl Acad Sci 2006;103(15):5941-6
36. Barun B, Bar-Or A. Treatment of multiple sclerosis with Anti-CD20 antibodies. Clin Immunol 2012;142(1):31-7
37. Gold R, Kappos L, Arnold DL, et al. Placebo-Controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med 2012;367(12):1098-107
38. Scannevin RH, Chollate S, Jung M-Y, et al. Fumarates promote cytoprotection of central nervous system cells against oxidative stress via the nuclear factor (Erythroid-Derived 2)-like 2 pathway. J Pharmacol Exp Ther 2012;341(1):274-84
39. Hoefnagel JJ, Thio HB, Willemze R, Bavinck JNB. Long-term safety aspects of systemic therapy with fumaric acid esters in severe psoriasis. Br J Dermatol 2003;149(2):363-9
40. Vidic-Dankovic B, Kosec D, Damjanovic M, et al. Leflunomide prevents the development of experimentally induced myasthenia gravis. Int J Immunopharmacol 1995;17(4):273-81
41. Bartlett RR, Anagnostopulos H, Zielinski T, et al. Effects of leflunomide on immune responses and models of inflammation. Springer Semin Immunopathol 1993;14(4):381-94
42. Korn T, Toyka K, Hartung HP, Jung S. Suppression of experimental autoimmune neuritis by leflunomide. Brain 2001;124(Pt 9):1791-802
43. Strand V, Cohen S, Schiff M, et al. Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Leflunomide Rheumatoid Arthritis Investigators Group. Arch Intern Med 1999;159(21):2542-50
44. Kremer JM, Genovese MC, Cannon GW, et al. Concomitant leflunomide therapy in patients with active rheumatoid arthritis despite stable doses of methotrexate. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 2002;137(9):726-33
45. Kaltwasser JP, Nash P, Gladman D, et al. Efficacy and safety of leflunomide in the treatment of psoriatic arthritis and psoriasis: A multinational, double-blind, randomized, placebo-controlled clinical trial. Arthritis Rheum 2004;50(6):1939-50
46. Silverman E, Mouy R, Spiegel L, et al. Leflunomide or methotrexate for juvenile rheumatoid arthritis. N Engl J Med 2005;352(16):1655-66
47. Chon WJ, Josephson MA. Leflunomide in renal transplantation. Expert Rev Clin Immunol 2011;7(3):273-81
48. Williams JW, Javaid B, Kadambi PV, et al. Leflunomide for polyomavirus type BK nephropathy. N Engl J Med 2005;352(11):1157-8
49. Greene S, Watanabe K, Braatz-Trulson J, Lou L. Inhibition of dihydroorotate dehydrogenase by the immunosuppressive agent leflunomide. Biochem Pharmacol 1995;50(6):861-7
50. Fox RI, Herrmann ML, Frangou CG, et al. Mechanism of action for leflunomide in rheumatoid arthritis. Clin Immunol 1999;93(3):198-208
51. Bruneau JM, Yea CM, Spinella-Jaegle S, et al. Purification of human dihydro-orotate dehydrogenase and its inhibition by A771726, the active metabolite of leflunomide. Biochem J 1998;336(Pt 2):299-303
52. Furst DE. Leflunomide, mycophenolic acid and matrix metalloproteinase inhibitors. Rheumatology (Oxford)1999;38(Suppl 2):14-18
53. Cherwinski HM, Byars N, Ballaron SJ, et al. Leflunomide interferes with pyrimidine nucleotide biosynthesis. Inflamm Res 1995;44(8):317-22
54. Siemasko KF, Chong AS, Williams JW, et al. Regulation of B cell function by the immunosuppressive agent leflunomide. Transplantation 1996;61(4):635-42
55. Ruckemann K, Fairbanks LD, Carrey EA, et al. Leflunomide inhibits pyrimidine de novo synthesis in mitogen-stimulated T-lymphocytes from healthy humans. J Biol Chem 1998;273(34):21682-91
56. Gonzalez-Alvaro I, Ortiz AM, Dominguez-Jimenez C, et al. Inhibition of tumour necrosis factor and IL-17 production by leflunomide involves the JAK/STAT pathway. Ann Rheum Dis 2009;68(10):1644-50
57. Siemasko K, Chong AS, Jack HM, et al. Inhibition of JAK3 and STAT6 tyrosine phosphorylation by the immunosuppressive drug leflunomide leads to a block in IgG1 production. J Immunol 1998;160(4):1581-8
58. Elder RT, Xu X, Williams JW, et al. The immunosuppressive metabolite of leflunomide, A771726, affects murine T cells through two biochemical mechanisms. J Immunol 1997;159(1):22-7
59. Manna SK, Aggarwal BB. Immunosuppressive leflunomide metabolite (A771726) blocks TNF-dependent nuclear factor-kappa B activation and gene expression. J Immunol 1999;162(4):2095-102
60. Deage V, Burger D, Dayer JM. Exposure of T lymphocytes to leflunomide but not to dexamethasone favors the production by monocytic cells of interleukin-1 receptor antagonist and the tissue-inhibitor of metalloproteinases-1 over that of interleukin-1beta and metalloproteinases. Eur Cytokine Netw 1998;9(4):663-8
61. Kraan MC, Reece RJ, Barg EC, et al. Modulation of inflammation and metalloproteinase expression in synovial tissue by leflunomide and methotrexate in patients with active rheumatoid arthritis. Findings in a prospective, randomized, double-blind, parallel-design clinical trial in thirty-nine patients at two centers. Arthritis Rheum 2000;43(8):1820-30
62. Korn T, Magnus T, Toyka K, Jung S. Modulation of effector cell functions in experimental autoimmune encephalomyelitis by leflunomide-mechanisms independent of pyrimidine depletion. J Leukoc Biol 2004;76(5):950-60
63. Limsakun T, Menguy-Vacheron F. Pharmacokinetics of oral teriflunomide, a novel oral disease-modifying agent under investigation for the treatment of multiple sclerosis. Neurology 2010;74:P 032
64. O'Connor PW, Li D, Freedman MS, et al. A phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses. Neurology 2006;66(6):894-900
65. Rozman B. Clinical pharmacokinetics of leflunomide. Clin Pharmacokinet 2002;41(6):421-30
66. Drug Approval Package Aubagio (Teriflunomide) tablets. Clinical Pharmacology and Biopharmaceutics Review(s): NDA992; 2011 August 12, 2011
67. Rakhila H, Rozek T, Hopkins A, et al. Quantitation of total and free teriflunomide (A771726) in human plasma by LC-MS/MS. J Pharm Biomed Anal 2011;55(2):325-31
68. Aubagio (teriflunomide) - Full Prescribing Information. 2012:1-27
69. Russo PA, Wiese MD, Smith MD, et al. Leflunomide for inflammatory arthritis in end-stage renal disease on peritoneal dialysis: A pharmacokinetic and pharmacogenetic study (March). Ann Pharmacother 2013;47(3):e15
70. Kis E, Nagy T, Jani M, et al. Leflunomide and its metabolite A771726 are high affinity substrates of BCRP: Implications for drug resistance. Ann Rheum Dis 2009;68(7):1201-7
71. Imai Y, Nakane M, Kage K, et al. C421A polymorphism in the human breast cancer resistance protein gene is associated with low expression of Q141K protein and low-level drug resistance. Mol Cancer Ther 2002;1(8):611-16
72. Kim KA, Joo HJ, Park JY. Effect of ABCG2 genotypes on the pharmacokinetics of A771726, an active metabolite of prodrug leflunomide, and association of A771726 exposure with serum uric acid level. Eur J Clin Pharmacol 2011;67(2):129-34
73. Confavreux C, Li DK, Freedman MS, et al. Long-term follow-up of a phase 2 study of oral teriflunomide in relapsing multiple sclerosis: Safety and efficacy results up to 8.5 years. Mult Scler 2012;18(9):1278-89
74. Freedman MS, Wolinsky JS, Wamil B, et al. Teriflunomide added to interferonin relapsing multiple sclerosis: A randomized phase II trial. Neurology 2012;78(23):1877-85
75. Freedman M, Wolinsky JS, Frangin GA. Oral teriflunomide on placebo added to glatiramer acetate for 6 months in patients with relapsing multiple sclerosis: Safety and efficacy results. Neurology 2010;74:abstract S21
76. O'Connor P, Wolinsky JS, Confavreux C, et al. Randomized trial of oral teriflunomide for relapsing multiple sclerosis. N Engl J Med 2011;365(14):1293-303